Investors Buy Large Volume of Put Options on Vor Biopharma (NYSE:VOR)

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) saw some unusual options trading on Tuesday. Investors bought 17,569 put options on the stock. This represents an increase of approximately 345% compared to the typical daily volume of 3,949 put options.

Analysts Set New Price Targets

Several research analysts have issued reports on VOR shares. HC Wainwright upgraded Vor Biopharma from a "neutral" rating to a "buy" rating and set a $3.00 price target on the stock in a report on Monday, June 30th. JMP Securities reaffirmed a "market perform" rating and set a $6.00 price target on shares of Vor Biopharma in a research report on Friday, May 9th. Oppenheimer reaffirmed an "outperform" rating and set a $8.00 price target on shares of Vor Biopharma in a research report on Friday, March 21st. Stifel Nicolaus decreased their price target on Vor Biopharma from $12.00 to $5.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, Citizens Jmp downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 9th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $5.63.

Vor Biopharma Price Performance

NYSE:VOR traded up $0.19 during mid-day trading on Wednesday, reaching $2.59. 14,804,557 shares of the company's stock traded hands, compared to its average volume of 4,595,034. Vor Biopharma has a 12-month low of $0.13 and a 12-month high of $3.29. The firm has a market capitalization of $323.40 million, a price-to-earnings ratio of -1.59 and a beta of 2.04. The company has a 50 day moving average price of $0.53 and a 200-day moving average price of $0.87.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Vor Biopharma during the 4th quarter valued at about $33,000. Money Concepts Capital Corp increased its holdings in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after purchasing an additional 26,535 shares during the period. Virtu Financial LLC purchased a new position in Vor Biopharma during the 4th quarter valued at about $60,000. XTX Topco Ltd purchased a new position in Vor Biopharma during the 4th quarter valued at about $80,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after acquiring an additional 58,247 shares during the period. Hedge funds and other institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.